Abbott Laboratories (Pakistan) Limited
By PSX Investors Zone · Updated October 20, 2026
Abbott Laboratories (Pakistan) Limited (PSX: ABOT) is a Pakistani pharmaceutical and healthcare company incorporated in 1948. Its business includes branded generic medicines, nutritional products, diagnostics, diabetes care, hospital products and consumer healthcare products. Explore its financial performance, dividend history, Shariah-screening status and key business risks before conducting further investment research.
Company Overview
Abbott Laboratories (Pakistan) Limited (PSX: ABOT) is a public limited company incorporated in Pakistan on July 2, 1948. The company operates in the pharmaceutical sector and manufactures, imports and markets a range of healthcare products.
Its business includes branded generic medicines, nutritional products, diagnostic products, diabetes-care products, molecular diagnostic devices, hospital products and consumer healthcare products.
Official sources: PSX Company Profile | Abbott Pakistan Official Website
Business Model
Abbott Pakistan serves healthcare professionals, hospitals, pharmacies, distributors and consumers through its pharmaceutical and healthcare product portfolio.
Its performance can be affected by medicine demand, product pricing, manufacturing costs, imported ingredients, foreign-exchange movements, regulatory approvals, competition and government healthcare policies.
Investors should review the company's annual report to understand its product categories, operating expenses, cash flows and business risks.
Source: Abbott Pakistan Investor Information
Financial Performance
Annual Results — FY2025
The following figures are from the standardized financial information displayed on PSX and the company's annual-report disclosures. Financial amounts are in Pakistani rupees.
| Financial Metric | FY2025 | FY2024 |
|---|---|---|
| Sales | Rs75.40 billion | Rs68.18 billion |
| Profit after taxation | Rs7.97 billion | Rs5.23 billion |
| Earnings per share (EPS) | Rs81.37 | Rs53.46 |
| Gross profit margin | 35.08% | 28.95% |
| Net profit margin | 10.57% | 7.68% |
Sales increased by approximately 10.6% in FY2025. Profit after taxation also increased compared with FY2024. These figures indicate improved reported performance, but investors should assess whether earnings growth is supported by sustainable operating results and cash generation.
Half-Year Results — June 2026
The company's half-year results cover the six months ended June 30, 2026. The figures below are calculated by combining the quarterly figures displayed on PSX for the first and second quarters.
| Financial Metric | H1 2026 |
|---|---|
| Sales | Approximately Rs38.03 billion |
| Profit after taxation | Approximately Rs4.14 billion |
| EPS | Approximately Rs42.29 |
These are calculated half-year totals based on the quarterly figures shown on the PSX profile, rather than separately transcribed totals from the original half-year report. Refer to the official report for the reported presentation and any accounting adjustments.
Sources: PSX Financials and Ratios | Abbott Pakistan Annual and Quarterly Reports
Dividend History
Abbott Pakistan's FY2025 annual report records a cash dividend of Rs10 per share in its appropriation details.
Investors should check the full annual report and subsequent PSX announcements for the complete distribution history, including any interim dividends, entitlement dates and payment details. Past dividend payments do not guarantee future distributions.
Sources: FY2025 Annual Report | PSX Company Announcements
Shariah Screening Status
The PSX KMI-30 recomposition notice published on May 15, 2026, listed Abbott Laboratories (Pakistan) Limited as Shariah-compliant, based on the screening exercise using financial information as of December 31, 2025. The PSX stock screener also lists ABOT in the KMI All Share Index.
This is a dated screening result, not a guarantee of permanent compliance. PSX revised its KMI screening methodology in February 2026, including a change to the interest-bearing debt-to-total-assets threshold. Investors should confirm the latest screening status and applicable methodology before relying on it.
Sources: Official PSX KMI-30 Recomposition Notice | PSX Stock Screener | PSX Methodology Revision
Important PSX Risk Warning
At the time of review on October 15, 2026, the official PSX company profile displayed a Risk Warning Alert referring to continuous violation of Clauses 5.11.1 or 5.11.2 and the risk of trading suspension or delisting.
This alert should not be interpreted as confirmation that trading has already been suspended or that the company has been delisted. Check the latest PSX notices and company disclosures to establish the current regulatory position.
Source: Official PSX ABOT Profile
Key Risks to Research
- Regulatory risk: Pharmaceutical products are subject to approvals, quality standards and healthcare regulations.
- Pricing pressure: Changes in medicine pricing policies can affect revenue and margins.
- Input costs: Imported ingredients and foreign-exchange movements can influence production costs.
- Competition: Domestic and international pharmaceutical companies compete across product categories.
- Product and quality risk: Product quality, supply continuity and regulatory compliance are important to operating performance.
- Earnings sustainability: A rise in annual profit does not guarantee that future earnings will grow at the same rate.
- PSX regulatory warning: Review the current Exchange alert and related notices before making any assessment.
These are general research considerations, not predictions of future share-price performance.
Investor Research Checklist
Before evaluating ABOT, review:
- The latest annual and interim financial statements.
- Revenue growth, profit margins, EPS and operating cash flow.
- Product categories and the company's reported operating performance.
- Imported input costs and foreign-exchange exposure.
- Dividend announcements and payment dates.
- Valuation compared with earnings and relevant pharmaceutical companies.
- The latest official Shariah-screening results.
- Current PSX notices, including the Risk Warning Alert.
Frequently Asked Questions
What does Abbott Laboratories (Pakistan) Limited do?
It manufactures, imports and markets pharmaceutical, nutritional, diagnostic, diabetes-care, hospital and consumer healthcare products.
What was ABOT's EPS in FY2025?
The company's reported FY2025 earnings per share were Rs81.37, according to its annual report and the standardized financial data displayed on PSX.
Is ABOT Shariah-compliant?
The PSX KMI-30 recomposition notice published in May 2026 listed ABOT as compliant based on the December 2025 screening data. Verify the latest official status before relying on it.
Disclaimer
This profile is for educational and informational purposes only. It is not personalized investment advice or a recommendation to buy, sell or hold ABOT shares. Verify current official disclosures, consider the risks and conduct independent research before making financial decisions.
This profile is for educational purposes and is not a recommendation to buy or sell any security.